The End of ACE Inhibitors? - Frankly Speaking EP 253Guest: Robert A. Baldor, MD, FAAFP
Music Credit: Richard Onorato
ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers) are both recommended as first-line treatments for hypertension. ACE inhibitors have known side effects, such as cough, that are frustrating for many patients, while ARBs appear to have less annoying side effects. This podcast will review a recently published retrospective, comparative cohort study comparing the effectiveness and safety of ACE inhibitors vs ARBs in the first-line treatment of hypertension.
Episode References and Resources:
- Hypertension. 2021;78:591–603. DOI: 10.1161/HYPERTENSIONAHA.120.16667
- ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–e248. doi: 10.1016/j.jacc.2017.11.006
Already listened on another platform?
- Apply the latest data regarding the efficacy and indications for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the treatment of hypertension
- Appreciate the risks and side effects of ACE inhibitors vs ARBs
- Consider prescribing ARBs as first-line treatment for hypertension
Supporters and Partners